Evidence map›Paper›PMID 29904421›Full record

ArticleExperimental and therapeutic medicine2018

Contrast-enhanced magnetic resonance imaging with a novel nano-size contrast agent for the clinical diagnosis of patients with lung cancer.

Jianwei Gao, Lei Li, Xia Liu, Rui Guo, Bin Zhao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. International journal of molecular sciences · 2023
    Article
  4. Role of GdOncology letters · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Jianwei GaoDepartment of MRI, Shandong Medical Imaging Research Institute, Shandong University, Jinan, Shandong 250021, P.R. China.
Lei LiDepartment of Interventional Radiology, The Second Affiliated Hospital of Qingdao University Medical College (Municipal Central Hospital of Qingdao), Qingdao, Shandong 266042, P.R. China.
Xia LiuDepartment of Radiology, Tai'an First People's Hospital, Tai'an, Shandong 271000, P.R. China.
Rui GuoDepartment of Gynecology and Obstetrics, Zhangqiu People's Hospital, Zhangqiu, Shandong 250200, P.R. China.
Bin ZhaoDepartment of MRI, Shandong Medical Imaging Research Institute, Shandong University, Jinan, Shandong 250021, P.R. China.
Shandong University · CNQingdao University · CNTaizhou First People's Hospital · CNZhangqiu City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have indicated that magnetic resonance imaging (MRI) efficiently diagnoses lung cancer. However, the efficacy of MRI in diagnosing lung cancer requires improving for patients in the early stage of the disease. In the present study, a novel nano-sized contrast agent of chistosan/Fe

Indexed as

chistosan/Fe3O4-enclosed bispecific antibodycontrast-enhanced magnetic resonance imaging-chistosan/Fe3O4-encapsulated bispecific antibodiesdiagnosislung cancermagnetic resonance imaging

Identifiers

PMID29904421
PMCPMC5996680
OpenAlexW2800909517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.